Key result
Sulfated glycoprotein-2 (SGP-2) expression in Sertoli cells is proposed to act as an endogenous inhibitor of ischemic injury, conferring resistance to ischemia and reperfusion.
SGP-2 is hypothesized to protect Sertoli cells from ischemia and reperfusion injury.
SGP-2 may underlie Sertoli resilience to ischemia; hypothesis-generating for targeted interventions in testicular injury.
Evidence of increased resistance of Sertoli cells to ischemia and reperfusion injury was presented by numerous histological, morphological, and quantitative studies. In situ hybridization techniques and immunocytochemical studies demonstrated intense expression of sulfated glycoprotein-2 (SGP-2) in Sertoli cells. We propose that protective effects of SGP-2 are the core of the differential tolerance of ischemia by the various testicular cells and the morphology of the postischemic testis. We believe that suppression of ischemic damage selectively in Sertoli cells is the consequence of the ability to produce SGP-2, an endogenous inhibitor of ischemic injury. This hypothetical function of SGP-2 is supported by its immunosuppressive properties and its structural and functional identity to several types of human complement cytolysis inhibitors.
No takes yet. Share an insight, caveat, or question.
Leibovitch et al. (1991) conducted a review in Ischemia and reperfusion injury in the seminiferous tubules. Sulfated glycoprotein-2 (SGP-2) was evaluated on Resistance to ischemia and reperfusion injury. Sulfated glycoprotein-2 (SGP-2) expression in Sertoli cells is proposed to act as an endogenous inhibitor of ischemic injury, conferring resistance to ischemia and reperfusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: